ImmunoPET: harnessing antibodies for imaging immune cells

被引：0
作者：
Anna M. Wu
Neeta Pandit-Taskar
机构：
[1] Beckman Research Institute,Department of Immunology and Theranostics, Arthur Riggs Diabetes and Metabolism Research Institute, Center for Theranostics Studies
[2] City of Hope,Department of Radiation Oncology
[3] City of Hope,Molecular Imaging &Therapy Svc, Department of Radiology
[4] Memorial Sloan Kettering Cancer Center,Center for Targeted Radioimmunotherapy and Theranostics, Ludwig Center for Cancer Immunotherapy
[5] Department of Radiology,undefined
[6] Weill Cornell Medical Center,undefined
[7] MSK,undefined
来源：
Molecular Imaging and Biology | 2022年 / 24卷
关键词：
ImmunoPET; Antibodies; Cancer; Immunotherapy; CD8; T cells;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dramatic, but uneven, progress in the development of immunotherapies for cancer has created a need for better diagnostic technologies including innovative non-invasive imaging approaches. This review discusses challenges and opportunities for molecular imaging in immuno-oncology and focuses on the unique role that antibodies can fill. ImmunoPET has been implemented for detection of immune cell subsets, activation and inhibitory biomarkers, tracking adoptively transferred cellular therapeutics, and many additional applications in preclinical models. Parallel progress in radionuclide availability and infrastructure supporting biopharmaceutical manufacturing has accelerated clinical translation. ImmunoPET is poised to provide key information on prognosis, patient selection, and monitoring immune responses to therapy in cancer and beyond.
引用
收藏
页码：181 / 197
页数：16
相关论文
共 109 条
[1]  
Atkins MB(1999)High-dose recomginant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 2105-2116
[2]  
Rosenberg SA(1988)Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N Engl J Med 319 1676-80
[3]  
Chen DS(2017)Elements of cancer immunity and the cancer-immune set point Nature 541 321-330
[4]  
Mellman I(2012)The immune contexture in human tumours: impact on clinical outcome Nat Rev Cancer 12 298-306
[5]  
Fridman WH(2014)Towards the introduction of the 'Immunoscore' in the classification of malignant tumours J Pathol 232 199-209
[6]  
Galon J(2019)Precision immunoprofiling by image analysis and artificial intelligence Virchows Arch 474 511-522
[7]  
Koelzer VH(2018)Single-cell RNA sequencing to explore immune cell heterogeneity Nat Rev Immunol 18 35-45
[8]  
Papalexi E(2016)Advances in PET Detection of the antitumor T cell response Adv Immunol 131 187-231
[9]  
Satija R(2016)[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity Proc Natl Acad Sci U S A 113 4027-4032
[10]  
McCracken MN(2011)Synthesis of 2'-deoxy-2'-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET Mol Imaging Biol 13 812-818
12345678910